Clinical research
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 4, 2020.
Imago BioSciences will announce preliminary results from its Phase IIb clinical trial for myelofibrosis (MF) at the 25th European Hematology Association (EHA) Annual Congress that begins June 12, 2020.
The company announced its Covance drug development business was launching COVID-19 Clinical Trial Connect in the U.S. to help people find information on taking part in clinical trials related to COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 3, 2020.
Of the Phase III trial, Fauci indicated that the majority of trial participants will be between the ages of 18 and 55, but will include elderly Americans that are most at risk of serious illness from COVID-19.
This morning, BMS said Zeposia achieved positive topline results in the Phase III True North clinical study in patients with moderate to severe ulcerative colitis.
Novus Therapeutics announced that its Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet its primary endpoint.
Pfizer shared results from the trial on Friday, and the data determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival in patients with breast cancer.
In the 5-day remdesivir group, patients were 65% more likely to see clinical improvement at 11 days compared to those treated with standard-of-care only.
PRESS RELEASES